RBC Capital Starts BioMarin Pharmaceutical (BMRN) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/31/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts BMRN Hot Sheet
Price: $58.51 +1.77%
Rating Summary:
25 Buy, 10 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Rating Summary:
25 Buy, 10 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Join SI Premium – FREE
RBC Capital initiates coverage on BioMarin Pharmaceutical (NASDAQ: BMRN) with an Outperform. PT $36.00.
For more ratings news on BioMarin Pharmaceutical click here and for the rating history of BioMarin Pharmaceutical click here.
Shares of BioMarin Pharmaceutical closed at $30.35 yesterday.
For more ratings news on BioMarin Pharmaceutical click here and for the rating history of BioMarin Pharmaceutical click here.
Shares of BioMarin Pharmaceutical closed at $30.35 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Baird Reiterates Neutral Rating on BioMarin Pharmaceutical Inc. (BMRN)
- Morgan Stanley Assumes Clarivate Plc (CLVT) at Underweight
- Cantor Fitzgerald Starts Pasqal SAS (PSQL) at Overweight
Create E-mail Alert Related Categories
New CoverageRelated Entities
RBC CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
